Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.
Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.